New cancer Drug's Real-World performance under scrutiny in korea
NCT ID NCT06581848
Summary
This study is monitoring the safety and effectiveness of the approved multiple myeloma drug Elranatamab in real-world Korean patients. It will track side effects and how well the drug works for 150 adults with advanced multiple myeloma who have already tried several other treatments. The goal is to understand how the drug performs in everyday clinical practice outside of controlled trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.